The rIl genetic region of phage T4 has been shown by Benzer to consist of two independent functional units or cistrons, A and B, in which over 300 distinct mutational sites have been resolved and ordered.' 2 The ability to analyze the structure of this region in great detail and the wealth of genetic knowledge thereby obtained3-10 has inspired several previous attempts in this laboratory and elsewhere to isolate a corresponding protein, but o10 success has been reported. The difficulty lies in the lack of an assay for these cistron products which are of unkinon function and are likely present in small amount in the infected cell.
The rIl genetic region of phage T4 has been shown by Benzer to consist of two independent functional units or cistrons, A and B, in which over 300 distinct mutational sites have been resolved and ordered.' 2 The ability to analyze the structure of this region in great detail and the wealth of genetic knowledge thereby obtained3-10 has inspired several previous attempts in this laboratory and elsewhere to isolate a corresponding protein, but o10 success has been reported. The difficulty lies in the lack of an assay for these cistron products which are of unkinon function and are likely present in small amount in the infected cell. This communication describes a new approach by which a peptide, resulting from enzymatic digestion of the total protein from T4-infected cells, can be identified as a fragment of the primary product of the rIl B cistron.
Materials and Methods.-rII mutants: All of the rnI mutants were derived from standard type T4B and have been described previously.2-4' 7 8 The composition of all multiple rfl mutants was verified by making appropriate backerosses and identifying the respective single mutant segregants.
Bacteria: E. coli strain T3A was the host used in all of the tryptophan labeling experiments reported here. This strain, obtained from Dr. Charles Yanofsky, is lysogenic for phage X, requires tryptophan for growth, and lacks tryptophanase activity."1 Media: For tryptophan labeling experiments the minimal M9 medium given by Adams'2 was used with two modifications: CG medium is basal M9 (without glucose) supplemented with 2% acid-hydrolyzed casamino acids and 50 ,ug/ml L-tryptophan; CS medium is CG without tryptophan. Overnight cultures of T3A were grown in CG medium supplemented with 1% glucose.
Enzymes: The trypsin used in all digestions had been treated with tosyl-L-phenylalanyl chloromethane to render it essentially free of chymotryptic activity and was obtained in this form from Calbiochem. DNase and RNase were from Worthington Biochemical Co.
Isotopically labeled tryptophan: L-tryptophan-3-C'4 at a specific activity of 20-25 c/mole was obtained from New England Nuclear Corp., and uniformly labeled L-tryptophan-H3 at 3300-4700 c/mole from Nuclear-Chicago. Solutions of these were stored at 40C.
Preparation and digestion of labeled infected-cell extracts: A 10-ml culture of E. coli T3A in CG medium was grown at 370C to a cell density of 4-5 X 108/ml and transferred by centrifugation to an equal volume of CS medium. The cells were aerated in CS medium for 40 min at 370C to deplete the residual tryptophan and then infected with phage at a multiplicity of 5 phage per bacterium. Three min later, at which time cell survival was less than 5%, the labeled amino acid was added (3.5 ,uc of C'4-tryptophan or 42 ,uc of H3-tryptophan), and 14 min later the culture was quickly chilled to 40C and the cells were collected by centrifugation. insoluble material (comprising usually some 15% of the C14), the soluble peptides were applied to the ion-exchange column. For double-label experiments the infected cultures were mixed before centrifugation in a proportion such that the H3/C'4-counting ratio of the TCA-insoluble material was usually 1.5 to 2.5.
Results.-The method used for detecting an rII specific product is to compare cell extracts from two infected cultures: the first was infected with an rII mutant blocked in the synthesis of the A cistron polypeptide and labeled with H3 amino acid; the second was infected with an nII mutant blocked in the synthesis of the B cistron polypeptide and labeled with C14 amino acid. Since previous attempts to detect the rII product by direct protein fractionation have been unsuccessful, the total protein of the infected cell extract was reduced to peptides by enzymatic hydrolysis, and the resulting digest was analyzed by ion-exchange column chromatography. The increase in the number of components due to hydrolysis was compensated for by using as a label an amino acid that, in general, occurs infre-(iluently in proteins. Since indirect genetic arguments suggest that tryptophat occurs in the rII protein (see ref. 13 ), this amino acid was chosen as the label.
The conditions of labeling were designed to provide a selective enrichment of label in rII protein by using as host a X lysogen infected with an rII mutant, since in this case protein synthesis ceases at about the time most phage particle precursor proteins would normally begin to appear.'4
Detection of a peptide whose appearance is affected by an rII B cistron ochre mutation: The initial comparison was made using the rII mutants rN55 and rUV375, whose locations on the genetic map are shown in 
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chosen for the following reasons: (1) Both rN55 and rIJ375 are ochre mutations, which are a class of mutations suspected to terminate synthesis of the polypeptide chain at the site of the mutation.6 16, 20 (Amber mutants were not used in the initial work because the rII restrictive host T3A, chosen for its tryptophan requirement, suppresses many amber mutations.) (2) rN55 and rUV375 are located near the left ends, respectively, of the A and B cistrons. This is the end, as suggested by previous genetic studies, at which translation begins.4 17 Thus rUV375 should fail to synthesize most of the B cistron polypeptide, and rN55 should fail to synthesize most of the A cistron polypeptide; the A cistron mutation would not be expected to reduce the amount of B cistron product since no polarity effects have been observed in the rII region.25 Figure 2a shows a chromatographic comparison of the soluble tryptic peptides prepared from rN55-infected cells labeled with H3-tryptophan and rUV375-infected cells labeled with C'4-tryptophan. The C14 and H3 profiles correspond quite closely throughout the entire chromatogram except in the region around fraction 125. In this region there occurs a minor peak (No. 30) labeled to a greater extent by H3 than by C14, indicating that rN55-infected cells produce this component but rUV375-infected cells do not. A more sensitve way of demonstrating this difference is by a plot of the H3 to C14 ratio as shown in Figure 2b . Although there are hints of other differences, the ratio is relatively constant except for component 30. A control experiment to test for impurities present in one label not present in the other was done by using rN55 for both the H3 and C14 labeling and is shown in Figure 2c . There are small deviations seen in both Figures 2b and c which may be due to impurities, but the large deviation around fraction 125 in Figure 2b certainly is not.
The above experiment was repeated using a different pair of ochre mutants. In this experiment C14-tryptophan was used as the label in both infected cultures and the comparison is between two separate chromatograms, the relevant parts of which are shown in Figure 3 . Again component 30 is present for the A cistron mutant (rN21) and absent for the B cistron mutant (rN7). It can also be seen from Figure 3 that the chromatographic analysis is highly reproducible.
That component 30 is, in fact, a peptide which contains tryptophan has been is a fragment of the polypeptide product of therII B cistron, it should be possible to localize the region of the cistron that determines its amino acid sequence. A rough localization of the right end of the region has been made by using deletion mutations which penetrate the B cistron from the right (see Fig. 1 ). One such deletion, rNB5060, because it does not recombine with the ochre rN7 tested above,
would not be expected to produce component 30 and this is, in fact, the case. Another deletion, rNB3034, which does not penetrate as far into the B cistron, does produce component 30. This result delimits the right end of the region to between the left ends of these deletions. Additional tests with ochre and phase-shift mutations distributed throughout the B cistron, shown in Figure 1 , confirm this result and localize the right end of the region more closely. Since genetic arguments indicate that the direction of translation of therlI region is from left to right, the mapping of the left end of the component 30 region presents a different problem than that of the right end because any chain-terminating mutation within or to the left of the region should result in the absence of the component. A possible way of determining the extent to the left is by means of mutually suppressing pairs of phase-shift mutations of the kind described by Crick et al. Figure 1 gives the results for 32 mutants tested for their ability to produce component 30. The component is present for all A cistron mutations (6 cases), absent for all mutations affecting the B cistron to the left of rNB3034 (19 cases) , and is present for all mutations affecting the B cistron to the right of the left end of rNB3034 (7 cases). These results, combined with those using phase-shift double mutants, localize the region of the B cistron that determines the occurrence of this peptide. It is unlikely that this peptide is derived from another protein whose synthesis is dependent on the rII B function since mutants which are lacking this function nevertheless can produce component 30.
The polarity of the B cistron as revealed by the location of mutations which eliminate component 30 confirms that the translation of the rII B cistron must proceed from the end adjoining the A cistron, which is the direction inferred from previous genetic studies. 4 17 Given this direction of translation, the fact that all ochre mutations in the B cistron, except those at the extreme right end, eliminate component 30 confirms other evidence that ochres, like ambers,"' 21 result in termination of the growing polypeptide chain.6' 16. 20 A triplet whose assignment has been uncertain from in vitro experiments is UGA, which has recently been shown by genetic experiments to be a third nonsense triplet in E. coli. 10 22 An rII mutation which creates UGA is rX655, shown in Figure 1. This mutation, like all the ochres and phase-shift mutations in its neighborhood, eliminates component 30, consistent with its being nonsense. However, had UGA specified cysteine, as suggested by some in vitro experiments,23 it could be argued that the creation of a cysteine in one part of the molecule could render another part of the molecule inaccessible to cleavage by trypsin.
More generally, the same objection could be raised to all cases in which component 30 is not found, since it is conceivable that changes in the amino acid sequence of regions of the polypeptide external to the component 30 region could reduce the yield of component 30 below the limit of detection, which is roughly 20 per cent. Thus, the presence of component 30 is to be taken as more significant than its absence. In the case of only one mutant, r1589, is the absence of component 30 inconsistent with other results. This mutant has been shown previously to retain B cistron activity, even though the left tip of the B cistron and the cistron divide between A and B have been deleted;"7 the deletion does not, however, penetrate the B cistron as far as rFC2227 and thus would be expected to produce component 30. A double-label comparison of r1589 with an A cistron mutant shows very little, if VrOL.,58, 1967 VrOL.,58, 1187 any, component 30 contributed by r1589. It is possible that the deletion of the left tip of the B cistron or the appended fragment of the A cistron reduces the enzymatic yield of component 30; alternatively, since the initiation site of the residual B cistron in r1589 is now that of the A cistron, the amount of B cistron product may be reduced.
The detection of a fragment of the rII B cistron polypeptide provides an assay for the intact polypeptide and thus an approach to its purification. Attempts in this direction are in progress.
Summary.-Tryptic digests of the total protein from T4 rIl-infected E. coli labeled after infection with tryptophan reveal a peptide whose occurrence is determined by a portion of the rII B cistron.
